

**In the Specification:**

Please replace the paragraph beginning at page 52, line 14 with the following:

A<sub>1</sub> --A fusion protein containing the two antigens TbH-9 and Tb38-1  
(hereinafter referred to as TbH9-Tb38-1) without a hinge sequence, was prepared using a  
similar procedure to that described above.--

Please cancel the present "SEQUENCE LISTING", pages 53-187, and insert therefor the  
accompanying paper copy of the Sequence Listing, page numbers 1 to 95, at the end of  
the application. Cancel the page numbers of the Claims and Abstract and renumber as  
pages 53-59, accordingly.

**REMARKS**

The "SEQUENCE LISTING", pages 53-187, submitted with the  
application filed on November 28, 2001 as a continuation of application 08/818,112, filed  
March 13, 1997, contains SEQ ID NOS:1-153. On page 12, lines 3-5, a description of  
SEQ ID NOS:154 and 155 as the DNA and amino acid sequences, respectively, of "*M.*  
*tuberculosis* antigen 38 kD" occurs. These sequences are not found in the instant  
application, but are found, as the identical SEQ ID NOS:154 and 155 or the priority  
application PCT/US 91/14674, which is incorporated by reference in its entirety on page  
6, lines 5-7. Therefore, the addition of these sequences to the Sequence Listing submitted  
herewith does not introduce new matter.


Applicants request entry of this amendment in adherence with 37 C.F.R.  
§§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above  
named sequences, SEQ ID NOS:1-155, in computer readable form, and a paper copy of  
the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy.

Attached hereto is a marked-up version of the changes made to the Specification by the current Amendment. The attached pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Kevin L. Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
KLB:dmw

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Paragraph beginning at line 14 of page 52 has been amended as follows:

A fusion protein containing the two antigens TbH-9 and Tb38-1 (hereinafter referred to as TbH9-Tb38-1) without a hinge sequence, was prepared using a similar procedure to that described above. ~~The DNA sequence for the TbH9-Tb38-1 fusion protein is provided in SEQ ID NO: 156.~~